Pharmaceutical companies often need support to assess commercial viability and define business models to expand access to new therapies across LMIC markets. We supported a leading pharmaceutical company to evaluate market opportunities for a dengue asset by analyzing demand, competitive dynamics, and barriers to adoption, and assessing pathways across large travelers’ markets including Singapore, Brazil, and the U.S. This informed the client’s investment decision and clarified viable business models to expand access while managing commercial risk.